Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial

Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial

Abstract Introduction Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection site pain (ISP) associated with subcutaneous administration may affect compliance or hinder initiat...

Full description

Bibliographic Details
Main Authors: Stanley Cohen, Ahmed Samad, Elaine Karis, Bradley S. Stolshek, Mona Trivedi, Hao Zhang, Girish A. Aras, Greg Kricorian, James B. Chung
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-03-01
Series:Rheumatology and Therapy
Subjects:
Etanercept
Injection site pain
Phosphate-free formulation
Psoriatic arthritis
Rheumatoid arthritis
Subcutaneous injection
Online Access:http://link.springer.com/article/10.1007/s40744-019-0152-8

Internet

http://link.springer.com/article/10.1007/s40744-019-0152-8

Similar Items